Rani Therapeutics, LLC, a clinical-stage biotherapeutics company focused on delivering biologics and drugs orally, has expanded its footprint in Silicon Valley with a new lease for 33,340 square feet of manufacturing and administrative space in Fremont. The company’s subsidiary Rani Therapeutics Holdings Inc. signed the lease expansion at 47709 Fremont Blvd., located within the Bayside Commons technology park owned by BKM Capital Partners.
Cushman & Wakefield’s team of Alex Lagemann, Brandon Bain and Erik Hallgrimson represented Rani in securing this new facility. With this strategic location along the I-880 Corridor close to their other existing facilities in North San Jose and Milpitas (totaling approximately 34,000 square feet), Rani is poised for continued growth as part of Silicon Valley’s thriving biotech/life sciences cluster.
This expansion further solidifies Silicon Valley as a key player in the global biotech industry.
